PROVOCHOLINE Drug Patent Profile

« Back to Dashboard

Which patents cover Provocholine, and when can generic versions of Provocholine launch?

Provocholine is a drug marketed by Methapharm and is included in one NDA.

The generic ingredient in PROVOCHOLINE is methacholine chloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the methacholine chloride profile page.

Summary for PROVOCHOLINE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	7
Patent Applications:	3,957
Drug Prices:	Drug price information for PROVOCHOLINE
What excipients (inactive ingredients) are in PROVOCHOLINE?	PROVOCHOLINE excipients list
DailyMed Link:	PROVOCHOLINE at DailyMed

See drug prices for PROVOCHOLINE

Recent Clinical Trials for PROVOCHOLINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Dr. Diane Lougheed	Phase 4
Queen's University	Phase 4
University of Saskatchewan	Phase 3

See all PROVOCHOLINE clinical trials

Pharmacology for PROVOCHOLINE

Drug Class	Cholinergic Receptor Agonist
Mechanism of Action	Cholinergic Agonists

US Patents and Regulatory Information for PROVOCHOLINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-001	Oct 31, 1986		RX	Yes	Yes
Methapharm	PROVOCHOLINE	methacholine chloride	FOR SOLUTION;INHALATION	019193-002	Aug 29, 2016		DISCN	Yes	No

Provocholine Market Dynamics and Financial Trajectory

Last updated: August 26, 2026

Provocholine is the U.S. brand for methacholine chloride inhalation powder, a diagnostic agent used in bronchial challenge testing for suspected bronchial airway hyperresponsiveness. Its market is small, specialized, and largely insulated from conventional generic substitution because demand depends on pulmonary-function laboratories, specialist diagnosis, and the availability of validated challenge-testing infrastructure. Methapharm Inc. controls the current U.S. commercial product, while public financial information does not disclose Provocholine-specific revenue or profitability.

What is Provocholine and how is it used?

Provocholine contains methacholine chloride, a synthetic choline ester that induces bronchoconstriction in susceptible patients. Clinicians administer incremental concentrations through a nebulizer and measure the resulting change in forced expiratory volume in one second, or FEV1.

The product is used primarily when asthma is suspected but baseline spirometry does not establish the diagnosis. A positive response supports airway hyperresponsiveness, while a negative test can reduce the likelihood of current asthma in the appropriate clinical setting.

Product and regulatory profile

Item	Detail
Brand	Provocholine
Active ingredient	Methacholine chloride
Dosage form	Powder for inhalation, reconstituted before use
Therapeutic category	Diagnostic bronchial challenge agent
U.S. regulatory pathway	New Drug Application
U.S. NDA	019453
Current commercial company	Methapharm Inc.
Primary use	Bronchial airway hyperresponsiveness testing
Administration setting	Pulmonary-function laboratories, hospitals, specialty clinics
Patient population	Patients evaluated for asthma or airway hyperresponsiveness
FDA status	Approved prescription diagnostic product

The FDA-approved label requires administration by trained personnel with resuscitation equipment and a short-acting bronchodilator available. Testing is contraindicated or inappropriate in patients with severe baseline airway obstruction, recent myocardial infarction or stroke, uncontrolled hypertension, or other conditions that increase the risk of induced bronchospasm.[1]

What is the market size for Provocholine?

Provocholine operates in a narrow diagnostic market rather than a large prescription-drug market. Public sources do not identify an audited global market size or Provocholine-specific annual sales.

Demand is linked to the number of bronchial challenge tests performed, not to the total number of asthma patients. The addressable population is therefore much smaller than the roughly hundreds of millions of people worldwide living with asthma.

Main demand drivers

Demand is supported by:

• Persistent diagnostic uncertainty in patients with asthma-like symptoms.
• Pulmonary specialists’ use of bronchoprovocation testing after nondiagnostic spirometry.
• Occupational asthma evaluations.
• Reimbursement for medically necessary pulmonary-function testing.
• Continued use of methacholine challenge testing in academic and hospital laboratories.
• Product familiarity among respiratory physicians and pulmonary-function technologists.

Demand is constrained by:

• Limited availability of specialized testing laboratories.
• Staff, equipment, and emergency-readiness requirements.
• Substitution by exercise challenge, eucapnic voluntary hyperventilation, fractional exhaled nitric oxide, or other diagnostic approaches.
• Reduced testing volume when clinicians make a clinical asthma diagnosis without provocation testing.
• Reimbursement pressure on diagnostic procedures.
• Testing delays caused by laboratory capacity and infection-control policies.

The commercial market has high clinical concentration. A relatively small number of hospital systems, academic centers, pulmonary practices, occupational-medicine programs, and diagnostic laboratories account for a significant share of demand.

How does Provocholine generate revenue?

Provocholine revenue is generated through sales of diagnostic kits to institutions and medical professionals. The product is not a chronic-use therapy and does not generate recurring monthly prescriptions from individual patients.

Revenue characteristics

Revenue factor	Effect on Provocholine
Treatment duration	One diagnostic procedure
Prescription refill behavior	Limited
Customer concentration	High; institutional buyers dominate
Volume sensitivity	Directly linked to test utilization
Pricing sensitivity	Moderate; diagnostic budgets and contracts influence purchasing
Inventory requirements	Laboratories must maintain product availability for scheduled testing
Switching costs	Moderate because protocols, staff training, and validation are product-specific
Reimbursement exposure	Material, because testing must be medically justified and reimbursed
Generic substitution	Limited in the U.S. market
Sales cycle	Institutional and specialty-channel oriented

The product’s unit economics can be favorable relative to manufacturing complexity because methacholine is an established small molecule and the product is sold for diagnostic use rather than continuous treatment. The commercial burden lies in regulatory compliance, packaging, quality control, distribution, medical education, and maintaining supply to specialized laboratories.

What is the financial trajectory of Provocholine?

Methapharm is a private company and does not publish product-level revenue, operating margins, unit volumes, or forecasts for Provocholine. No reliable public series establishes annual Provocholine sales.

The likely financial trajectory is one of mature, stable specialty-product revenue rather than rapid growth. The product has a defined clinical role, a relatively narrow customer base, and limited exposure to mass-market pharmaceutical competition.

Financial trajectory by phase

Period	Commercial pattern
Initial commercialization	Market creation around standardized methacholine challenge testing
Mature adoption	Stable use in pulmonary and academic testing centers
Recent period	Demand influenced by laboratory utilization, diagnostic guidelines, and supply continuity
Forward outlook	Low- to mid-single-digit volume variability is more plausible than high-growth expansion, but public company guidance is unavailable

Revenue upside depends on expansion of testing capacity and improved recognition of objective asthma diagnosis. Revenue downside is more likely to arise from reduced procedure volumes, institutional budget controls, alternative diagnostic methods, or supply interruption than from a major competing branded drug.

A useful financial model would treat Provocholine as a niche diagnostic franchise with:

1. A limited number of institutional accounts.
2. High dependence on repeat laboratory purchasing.
3. Low patient-level adherence risk.
4. Moderate pricing power if supply is reliable.
5. Meaningful operational risk from manufacturing or distribution disruption.
6. Limited patent-driven protection and greater reliance on regulatory status, brand recognition, and supply execution.

What patents protect Provocholine?

Provocholine’s commercial protection does not appear to depend on a significant active-ingredient patent estate. Methacholine chloride is an old compound, and the product’s competitive position is primarily based on regulatory approval, manufacturing controls, product know-how, distribution, and clinical familiarity.

Patent and exclusivity profile

Protection category	Provocholine position
Active-ingredient patent	No commercially meaningful modern composition-of-matter protection expected
New chemical entity exclusivity	Expired or not commercially relevant
Formulation patent	No widely identified blocking formulation estate
Method-of-use patent	No dominant patent protection identified for routine bronchial challenge testing
Orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Regulatory exclusivity	Historical approval-related protection has expired
Current moat	Regulatory compliance, manufacturing capability, institutional adoption, and supply reliability

The absence of a strong current patent estate does not automatically produce immediate generic competition. A competing manufacturer would still need to develop a compliant product, submit an abbreviated or full application as appropriate, demonstrate pharmaceutical quality, establish manufacturing controls, and obtain acceptance from pulmonary laboratories.

What is the Orange Book status of Provocholine?

Provocholine is associated with FDA-approved NDA 019453. The Orange Book is the relevant source for approved drug applications, therapeutic-equivalence evaluations, and listed patents where applicable.[2]

For a niche diagnostic product, Orange Book exposure is less important than it is for a high-revenue chronic medicine. If no unexpired patent is listed against the product, a competitor could pursue an abbreviated application without needing to challenge a live patent, subject to FDA requirements and the availability of an appropriate reference product.

No major, currently active Orange Book patent barrier is widely associated with Provocholine. The commercial risk therefore comes from potential product development and approval by a competitor rather than from a near-term patent expiry event.

When does Provocholine lose exclusivity?

Provocholine’s core market exclusivity has already matured beyond the conventional patent and regulatory-exclusivity period. There is no commercially relevant future loss-of-exclusivity date comparable to the patent cliff for a modern blockbuster.

The practical distinction is between legal exclusivity and commercial defensibility:

• Legal exclusivity: limited or expired.
• Regulatory approval: remains necessary for lawful marketing.
• Manufacturing know-how: may slow entry but is not equivalent to patent exclusivity.
• Customer relationships: can support retention in a specialized market.
• Supply reliability: can create short-term share advantages.
• Clinical familiarity: may reduce switching to an unfamiliar entrant.

This structure makes Provocholine vulnerable to an approved competitor, but it also reduces the incentive for large pharmaceutical companies to pursue the product because the addressable market is limited.

Are there Paragraph IV challenges to Provocholine?

A Paragraph IV challenge is used when an abbreviated new drug application applicant asserts that a listed patent is invalid, unenforceable, or not infringed. Such litigation is common for high-value branded drugs with substantial remaining patent life.

No prominent public Paragraph IV litigation campaign is associated with Provocholine in the principal federal pharmaceutical-litigation record. The absence of a visible Paragraph IV dispute is consistent with the product’s mature status, limited market size, and lack of a high-value active patent estate.

A potential entrant would likely focus on regulatory and commercial execution rather than on challenging a valuable remaining patent.

Which companies compete with Provocholine?

Competition occurs at two levels: direct methacholine-product competition and diagnostic substitution.

Direct competition

The U.S. market appears concentrated around Provocholine as the established FDA-approved methacholine challenge product. A direct entrant would need to offer equivalent concentration preparation, consistent performance, dependable supply, and a regulatory package acceptable to pulmonary laboratories.

Diagnostic alternatives

Alternative	Competitive effect
Exercise challenge testing	Useful where exercise-induced bronchoconstriction is suspected
Eucapnic voluntary hyperventilation	Relevant in selected exercise and occupational evaluations
Mannitol challenge	Provides an alternative bronchial provocation approach in some markets
Fractional exhaled nitric oxide	Measures airway inflammation rather than directly reproducing methacholine challenge
Serial peak-flow monitoring	Useful for selected occupational or variable-symptom assessments
Clinical diagnosis plus spirometry	Reduces demand for provocation testing when findings are clear

These alternatives do not provide perfect therapeutic equivalence. Methacholine challenge remains useful because it directly assesses airway hyperresponsiveness and is familiar to respiratory specialists.

What formulation and manufacturing protections matter?

Provocholine is supplied as a powder that is reconstituted into solutions of specified concentrations for inhalation challenge testing. Manufacturing quality is important because the test depends on accurate concentration preparation and reproducible bronchoconstrictive response.

Operational barriers include:

• Active pharmaceutical ingredient qualification.
• Control of powder potency and purity.
• Stability during storage.
• Packaging suitable for institutional use.
• Validated reconstitution instructions.
• Batch-to-batch consistency.
• Microbiological and chemical quality controls.
• Accurate labeling of challenge concentrations.
• Distribution to laboratories that may hold limited safety stock.

These barriers are meaningful but do not create the same level of protection as a patent. A capable generic or specialty manufacturer could potentially replicate the product if the regulatory pathway and commercial economics justify the investment.

What FDA regulatory risks affect Provocholine?

The main regulatory risks are product quality, labeling, safety, and supply continuity.

The FDA-approved label emphasizes that bronchial challenge testing must be performed under controlled conditions with trained personnel and immediate access to rescue treatment.[1] A manufacturing or labeling issue could affect laboratory confidence and produce temporary demand disruption.

The product also depends on continued recognition of methacholine challenge testing within clinical practice. The American Thoracic Society and European Respiratory Society have published technical standards covering bronchial challenge testing, including test performance and interpretation.[3]

What generic entry risks exist for Provocholine?

Generic entry risk is real but probably gradual rather than imminent in the absence of a disclosed entrant.

Scenario analysis

Scenario	Market effect	Probability profile
No approved direct entrant	Provocholine retains specialist share and pricing stability	Base commercial case
One approved competitor	Price pressure and account-level switching	Moderate long-term risk
Multiple competitors	Lower prices, tender competition, and reduced brand leverage	Lower probability because market size is limited
Supply disruption	Temporary share loss or laboratory substitution	Material operating risk
Diagnostic substitution	Gradual volume erosion	Ongoing structural risk
Guideline-driven expansion	Higher test utilization	Upside case

The highest-value defensive asset is likely reliable supply combined with laboratory acceptance. In a small market, a competitor may fail to achieve scale even after regulatory approval if laboratories are satisfied with Provocholine and switching offers little economic benefit.

How strong is the Provocholine commercial position?

Provocholine has a moderate commercial position and a weak traditional patent position.

Strengths

• Established FDA-approved brand.
• Clear use in bronchial challenge testing.
• Specialist customer base with product familiarity.
• Limited direct U.S. competition.
• Repeat institutional purchasing.
• Clinical protocols built around methacholine testing.

Weaknesses

• Small addressable market.
• No apparent durable composition-of-matter patent moat.
• Limited public financial transparency.
• Dependence on pulmonary laboratory capacity.
• Exposure to diagnostic alternatives.
• Potential vulnerability to a lower-priced approved entrant.
• Concentrated customer base.

The product is better characterized as a defensible specialty diagnostic franchise than as a protected pharmaceutical growth asset.

What licensing deals affect Provocholine?

No major publicly disclosed licensing transaction currently defines Provocholine’s market position. The product is marketed by Methapharm, a specialty pharmaceutical company with a portfolio that includes hospital and diagnostic products. Public disclosures do not establish a large multinational licensing structure or co-commercialization arrangement for Provocholine.

Any valuation of the asset should therefore avoid assuming royalty streams or milestone payments that are not publicly documented.

What is the investment and commercial outlook for Provocholine?

Provocholine’s outlook is stable but constrained. The product can generate durable niche revenue if Methapharm maintains supply, regulatory compliance, and laboratory relationships. Growth is more likely to come from increased diagnostic utilization than from patient population expansion.

The asset may appeal to specialty-pharmaceutical buyers seeking:

• A mature product with established clinical use.
• Institutional rather than consumer marketing requirements.
• Potential price optimization.
• Manufacturing or distribution synergies.
• A platform position in pulmonary diagnostics.

It is less attractive to buyers seeking:

• Blockbuster revenue potential.
• Long-dated patent protection.
• Strong international exclusivity.
• High-growth prescription expansion.
• Large-scale sales-force leverage.

Key Takeaways

• Provocholine is methacholine chloride inhalation powder used for bronchial challenge testing.
• Methapharm Inc. is the current U.S. commercial company.
• The product has an established FDA approval under NDA 019453.
• Public sources do not disclose Provocholine-specific revenue, margins, or annual unit volume.
• Its financial profile is likely mature and specialty-oriented, with revenue tied to pulmonary-function laboratory utilization.
• The product does not appear to have a meaningful current patent moat.
• No prominent Paragraph IV challenge or major patent litigation campaign is associated with Provocholine.
• Direct competition is limited, but diagnostic alternatives create gradual volume pressure.
• The principal commercial defenses are regulatory compliance, supply reliability, clinical familiarity, and institutional relationships.
• The principal downside risks are generic entry, diagnostic substitution, reimbursement pressure, and manufacturing disruption.

FAQs

Is Provocholine a treatment for asthma?

No. Provocholine is a diagnostic agent used to provoke bronchoconstriction during testing for airway hyperresponsiveness. It does not treat asthma.

Does Provocholine have biosimilar risk?

No. Biosimilars apply to biologic products. Provocholine contains methacholine chloride, a small-molecule drug. Any competitor would pursue a generic or other applicable small-molecule approval pathway, not a biosimilar pathway.

Can a hospital substitute another methacholine product for Provocholine?

Substitution depends on regulatory approval, product specifications, laboratory validation, supply, and institutional protocols. A hospital cannot assume that an unapproved or differently configured product is therapeutically equivalent.

Is Provocholine exposed to a major patent cliff?

No major future patent cliff is evident. The more relevant risk is entry by an approved competitor into a mature market with limited legal exclusivity.

What would increase Provocholine revenue?

Higher utilization of objective asthma testing, greater pulmonary-laboratory capacity, broader occupational-asthma testing, improved reimbursement, and continued product availability would support revenue growth.

References

1. U.S. Food and Drug Administration. (n.d.). Provocholine (methacholine chloride) inhalation powder prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. Coates, A. L., Wanger, J., Cockcroft, D. W., Culver, B. H., Diamant, Z., Brusasco, V., et al. (2017). ERS technical standard on bronchial challenge testing: General considerations and performance of methacholine challenge tests. European Respiratory Journal, 49(5), 1601526.

4. Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. Global Initiative for Asthma.

5. Methapharm Inc. (n.d.). Provocholine product information. Methapharm Inc.